Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction

JAMA

Volumn 302, Issue 8, 2009, Pages 866-873

  Nanda, Akash ^a   Chen, Ming Hui ^b   Braccioforte, Michelle H ^c   Moran, Brian J ^c   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c Prostate Cancer Foundation of Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; CESIUM; FLUTAMIDE; GOSERELIN; IODINE; LEUPRORELIN; PALLADIUM; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

ADVANCED CANCER; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FOLLOW UP; HEART INFARCTION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SCORING SYSTEM; ADJUVANT THERAPY; DIABETES MELLITUS; DRUG POTENTIATION; HEART FAILURE; HYPERCHOLESTEROLEMIA; HYPERTENSION; KAPLAN MEIER METHOD; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; GONADOTROPIN-RELEASING HORMONE; HEART FAILURE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; KAPLAN-MEIERS ESTIMATE; MALE; MYOCARDIAL INFARCTION; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 69249229866     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1137     Document Type: Article

References (46)

1. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice: localized prostate cancer. NEngl J Med. 2007; 357(26):2696-2705.
2. Zelefsky MJ, Nedelka MA, Arican ZL, et al. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensitymodulated radiation therapy. Brachytherapy. 2008; 7(1):1-6.
3. Zelefsky MJ, Yamada Y, Cohen GN, et al. Fiveyear outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67(1):65-70. (Pubitemid 44959499)
4. Stock RG, Cesaretti JA, Stone NN. Diseasespecific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys. 2006;64(3):810-816.
5. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007;67(1):57-64.
6. Potters L, Torre T, Ashley R, Leibel S. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol. 2000;18(6):1187-1192. (Pubitemid 30159835)
7. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71(2):318-322. (Pubitemid 351282338)
8. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599-603. (Pubitemid 34158224)
9. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005;104(8):1633- 1637. (Pubitemid 41437426)
10. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24(27):4448-4456. (Pubitemid 46630983)
11. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979-3983. (Pubitemid 46630747)
12. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25(17):2420-2425. (Pubitemid 46999213)
13. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99(20):1516-1524. (Pubitemid 351767235)
14. Denham JW, Steigler A, Lamb DS, et al; Trans- Tasman Radiation Oncology Group. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans- Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6(11):841-850. (Pubitemid 41614795)
15. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50(5):1243-1252. (Pubitemid 32727802)
16. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292(7):821-827. (Pubitemid 39079668)
17. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103-106. (Pubitemid 34786197)
18. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005; 61(5):1285-1290. (Pubitemid 40470408)
19. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289-295. (Pubitemid 351159365)
20. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20(7):1183-1197. (Pubitemid 27274286)
21. Genuth S, Alberti KG, Bennett P, et al; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160-3167.
22. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997; 157(21):2413-2446. (Pubitemid 27517978)
23. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-2572.
24. Ansell BJ, Watson KE, Fogelman AM; National Cholesterol Education Program. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. JAMA. 1999;282(21):2051-2057.
25. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106 (25):3143-3421.
26. Nomenclature and criteria for diagnosis of ischemic heart disease: report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation. 1979;59(3): 607-609.
27. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/ American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36(3):959-969. (Pubitemid 30681627)
28. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38(7): 2101-2113.
29. Hunt SA, Abraham WT, Chin MH, et al. ACC/ AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154-e235.
30. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999; 44(4):789-799.
31. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974. (Pubitemid 28445094)
32. Agresti A. Categorical Data Analysis. 2nd ed. New York, NY: John Wiley & Sons; 2002.
33. Hollander M, Wolfe DA. Nonparametric Statistical Methods. 2nd ed. New York, NY: John Wiley & Sons; 1999.
34. Newgard CD, Hedges JR, Arthur M, Mullins RJ. Advanced statistics: the propensity score - a method for estimating treatment effect in observational research. Acad Emerg Med. 2004;11(9):953-961. (Pubitemid 39149929)
35. Klein JP, Moeschberger ML. Survival Analysis. New York, NY: Springer-Verlag; 2003.
36. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. Philadelphia, PA: Lippincott; 2002.
37. Cupples LA, Gagnon DR, Ramaswamy R, D'Agostino RB. Age-adjusted survival curves with application in the Framingham Study. Stat Med. 1995; 14(16):1731-1744.
38. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53:457-481.
39. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-170.
40. Shaffer JP. Multiple hypothesis-testing. Annu Rev Psychol. 1995;46:561-584.
41. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 2000; 21(6):552-560. (Pubitemid 32056218)
42. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65(3):669-677. (Pubitemid 43795860)
43. Beyer DC, McKeough T, Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61(5):1299-1305. (Pubitemid 40470410)
44. Sesso HD, Lee IM, Gaziano JM, Rexrode KM, Glynn RJ, Buring JE. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation. 2001;104(4):393-398.
45. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952. (Pubitemid 39208455)
46. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004; 291(20):2441-2447. (Pubitemid 38669187)